Bacterial prostatitis – European Clinical Trials Information Network

Short-course (7‑day) versus standard 14‑day ciprofloxacin treatment for men with serious urinary tract infection

Wed, 13 May 2026 05:05:05 +0000

A Urinary tract infection that spreads beyond the bladder and causes fever, flank pain, low blood pressure, or high levels of inflammation in the blood is being studied. The infection is treated with the oral antibiotic ciprofloxacin, which is taken as a tablet. In some cases a matching placebo capsule that looks the same as the antibiotic may be used to keep the study blinded.

The purpose of the study is to determine whether a shorter, 7‑day course of the antibiotic works as well as the standard 14‑day course in achieving a cure of the infection.

Participants are randomly assigned to receive either the short or the longer treatment. After finishing the medication, they are followed up with visits about two weeks and four weeks later to check whether symptoms have resolved, whether the infection has returned, and whether any side effects have occurred. “Clinical cure” means the patient’s signs and symptoms have returned to normal and no additional antibiotics are needed.

Study on Fosfomycin for Treating Acute Bacterial Prostatitis in Patients with Multidrug-Resistant E. coli

Wed, 29 Apr 2026 15:02:48 +0000

This clinical trial is focused on studying the treatment of acute bacterial prostatitis, a condition that affects the prostate gland and is caused by bacteria. Specifically, the study is looking at cases where the infection is due to multidrug-resistant Escherichia coli, a type of bacteria that is resistant to many common antibiotics. The treatment being tested in this study is an oral medication called fosfomycin, which is an antibiotic that can be taken by mouth as a solution.

The purpose of the study is to evaluate the effectiveness of fosfomycin in treating this type of prostatitis. Participants in the study will receive the medication for a period of up to three days. The study will compare the results of those taking fosfomycin with a control group who are treated with other approved therapies for infections caused by non-resistant strains of Escherichia coli.

Throughout the study, participants will be monitored to assess how well the treatment works in managing the infection. The goal is to determine if fosfomycin is a viable alternative for treating this challenging condition, especially in cases where the bacteria are resistant to other treatments. This research could provide valuable insights into new ways to manage infections that are difficult to treat with standard antibiotics.

Study on the Effectiveness of Fosfomycin, Cefixime, and Ciprofloxacin in Treating Acute Bacterial Prostatitis in Adult Men

Wed, 29 Apr 2026 15:00:24 +0000

This clinical trial is focused on studying the treatment of acute bacterial prostatitis, a condition that causes inflammation of the prostate gland due to bacterial infection. The study will compare the effectiveness of two oral medications: Fosfomycin and Cefixime. Additionally, Ciprofloxacin Hydrochloride is another medication involved in the study. These medications are known as antimicrobials, which help fight infections caused by bacteria.

The purpose of the study is to evaluate how well these medications can resolve urinary symptoms associated with acute bacterial prostatitis. Participants will be randomly assigned to receive one of the medications or a placebo. The study will monitor the reduction of symptoms such as fever and urinary discomfort over a period of 6 to 10 days after the end of the treatment. The study aims to determine if the medications can effectively cure the infection without the need for additional antibiotics.

Participants will take the medication orally, and the treatment period will last up to 20 days. The study will involve regular check-ups to assess the improvement of symptoms and ensure the safety of the participants. The ultimate goal is to find the most effective treatment option for acute bacterial prostatitis, helping patients recover from this condition more efficiently.